News
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
AstraZeneca PLC closed 23.78% short of its 52-week high of £133.88, which the company achieved on September 3rd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback